Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Ocuphire Pharma granted new US patent for APX3330 » 09:07
06/29/22
06/29
09:07
06/29/22
09:07
OCUP

Ocuphire Pharma

$1.96 /

-0.06 (-2.97%)

Ocuphire Pharma announced…

Ocuphire Pharma announced that the United States Patent and Trademark Office, USPTO, has issued a new patent extending expiry and broadening coverage of the company's late-stage oral product candidate, APX3330. In addition, a new publication supporting the novel mechanism of action inhibiting NFkB and the inflammation pathway for APX3330 and the APX pipeline candidates has been published in a peer-reviewed journal. "We are pleased to announce the issuance of a new U.S. patent that further strengthens our patent estate for APX3330," said Mina Sooch, MBA, Founder and CEO of Ocuphire Pharma. "If approved, oral APX3330 has the potential to address the high unmet need for early intervention for progressive vision-threatening diabetic eye disease, including diabetic retinopathy and diabetic macular edema. The timing is ideal as we continue to advance our fully enrolled clinical program investigating APX3330 in DR/DME where we have reported interim masked safety results at multiple medical meetings throughout this year demonstrating a consistent and favorable safety profile for a first-in-class oral treatment option. Top-line results from the Phase 2b ZETA-1 trial are expected in the second half of 2022." U.S. Patent No. 11,351,130 has claims directed to methods of treatment using APX3330, which makes it eligible for listing in the U.S. FDA Orange Book. It was issued on June 7, 2022 and has a term that expires in year 2038. Claims in this patent include methods of treating inflammation and chronic pain in a subject suffering from diabetes. Ocuphire also announced the publication of a preclinical study outlining the pivotal role of NFkB in Ref-1 inhibition in a pancreatic ductal adenocarcinoma cell model with a Kras genotype and offers evidence of anti-inflammatory benefits of APX3330 in PDAC.

ShowHide Related Items >><<
OCUP Ocuphire Pharma
$1.96 /

-0.06 (-2.97%)

OCUP Ocuphire Pharma
$1.96 /

-0.06 (-2.97%)

05/19/22 Alliance Global Partners
Alliance Global Partners says Ocuphire's Nyxol trial run 'remarkable'
11/24/21 H.C. Wainwright
Ocuphire Pharma initiated with a Buy at H.C. Wainwright
10/06/21 Spartan Capital
Ocuphire Pharma initiated with a Buy at Spartan Capital
OCUP Ocuphire Pharma
$1.96 /

-0.06 (-2.97%)

Hot Stocks
Ocuphire Pharma to present interim masked safety data for oral APX3330 » 08:13
06/08/22
06/08
08:13
06/08/22
08:13
OCUP

Ocuphire Pharma

$2.09 /

+0.04 (+1.95%)

Ocuphire Pharma announced…

Ocuphire Pharma announced an oral presentation by key thought leader David Boyer, M.D. at the 45th Annual Macula Society Meeting, which will take place in Berlin, Germany from June 8-11, 2022. In addition, Mina Sooch, CEO and founder of Ocuphire Pharma, will participate in a virtual ophthalmology panel discussion hosted by Cantor Fitzgerald today, June 8th, at 10am EDT. "APX3330 is a novel non-invasive oral therapy, which if approved, has the potential to address the large unmet needs in diabetic retinopathy patients and other diabetes-related complications," said David Boyer, MD, Senior Partner at Retina-Vitreous Associates Medical Group, Medical Adviser to Ocuphire, and Investigator in the ZETA-1 trial. "The ongoing ZETA-1 Phase 2b trial is expected to provide valuable insights into the drug's safety and efficacy in diabetics. In February 2022, I presented early masked safety data from the trial at the Bascom Palmer Eye Institute Angiogenesis 2022 conference, which demonstrated a favorable safety and tolerability profile similar to 11 prior trials in non-ophthalmic indications. Now, with 70% of subjects through 12 weeks or more of the 24-week trial, I am excited to present new favorable and consistent safety data to an international audience at the Macula Society Meeting. Ocuphire continues to make an impression on the retinal community through numerous abstract presentations at major medical conferences."

ShowHide Related Items >><<
OCUP Ocuphire Pharma
$2.09 /

+0.04 (+1.95%)

OCUP Ocuphire Pharma
$2.09 /

+0.04 (+1.95%)

05/19/22 Alliance Global Partners
Alliance Global Partners says Ocuphire's Nyxol trial run 'remarkable'
11/24/21 H.C. Wainwright
Ocuphire Pharma initiated with a Buy at H.C. Wainwright
10/06/21 Spartan Capital
Ocuphire Pharma initiated with a Buy at Spartan Capital
OCUP Ocuphire Pharma
$2.09 /

+0.04 (+1.95%)

OCUP Ocuphire Pharma
$2.09 /

+0.04 (+1.95%)

Over a month ago
Recommendations
Alliance Global Partners says Ocuphire's Nyxol trial run 'remarkable' » 14:43
05/19/22
05/19
14:43
05/19/22
14:43
OCUP

Ocuphire Pharma

$2.03 /

-0.095 (-4.48%)

After Ocuphire Pharma…

After Ocuphire Pharma announced positive Phase 3 topline result in the LYNX-1 trial of Nyxol for dim light or night vision disturbances, Alliance Global Partners analyst James Molloy said this is the fourth positive Phase 2 or Phase 3 trial in a row where Nyxol has shown statistically significant results. Calling this "a remarkable achievement for any company, not least a small-cap company" such as Ocuphire, Molloy said he anticipates that the company could have clarity on the clinical path forward by the second half of 2022. Molloy reiterates a Buy rating and $25 price target on Ocuphire shares, which are down 10c, or 4%, to $2.03 in afternoon trading.

ShowHide Related Items >><<
OCUP Ocuphire Pharma
$2.03 /

-0.095 (-4.48%)

OCUP Ocuphire Pharma
$2.03 /

-0.095 (-4.48%)

11/24/21 H.C. Wainwright
Ocuphire Pharma initiated with a Buy at H.C. Wainwright
10/06/21 Spartan Capital
Ocuphire Pharma initiated with a Buy at Spartan Capital
06/01/21 JonesTrading
Jones Trading bullish on Ocuphire, sees 'under the radar' revenue opportunity
OCUP Ocuphire Pharma
$2.03 /

-0.095 (-4.48%)

OCUP Ocuphire Pharma
$2.03 /

-0.095 (-4.48%)

Hot Stocks
Ocuphire Pharma says LYNX-1 Phase 3 trial met primary endpoint » 07:32
05/19/22
05/19
07:32
05/19/22
07:32
OCUP

Ocuphire Pharma

$2.12 /

-0.075 (-3.42%)

Ocuphire Pharma announced…

Ocuphire Pharma announced topline results from the LYNX-1 Phase 3 pivotal clinical trial investigating its product candidate Nyxol for night vision disturbances. Across 12 US clinical trials with approximately 1100 subjects, over 650 subjects have now been exposed to Nyxol. NVD is a condition in which unfocused rays of light derived from imperfections in the periphery of the cornea manifest as reduced image quality when the pupil dilates in dim light conditions. Patients with NVD experience glare, halos, starbursts, and decreased contrast sensitivity. The effects of NVD can be mitigated by moderately reducing pupil diameter to eliminate some of the aberrations and their scattering effect, without impeding the ability to see in dim light due to reduced retinal illumination. Highlights of LYNX-1 NVD Phase 3 Results" LYNX-1 is a registration trial for Nyxol in this chronic NVD indication, and was designed as a randomized, double-masked, placebo-controlled, Phase 3 study to evaluate the safety and efficacy of Nyxol compared to placebo. In the trial, 145 study participants who experienced vision impairment under dim light conditions were randomized to receive either Nyxol or placebo, self-administered in each eye daily, at or near bedtime, over 14 days. The primary endpoint was the gain of 3 lines or more of distance vision improvement on a low contrast chart in dim light conditions. Baseline demographics and ocular characteristic means were well-balanced across Nyxol and placebo treatment arms. Highlights of the patient population include a mean age of 46 years with participants ranging from 19 to 70 years old; subjects with a mix of light and dark irides; mean baseline mesopic pupil diameter of 6.1 mm; and mean distance visual acuity of only 17 letters under mesopic low contrast conditions. Summary of LYNX-1 Data: The FDA-agreed primary endpoint was met, with a statistically significant greater percentage of Nyxol-treated subjects having gained 15 or more letters of mesopic low contrast distance visual acuity at Day 8, compared to placebo. Key secondary efficacy endpoints were also met with statistical significance: The effect of Nyxol increased at Day 15, with 21% of subjects gaining 15 or more letters of mLCVA compared to 3% placebo; Nyxol significantly increased the percentage of subjects gaining 10 or more letters of mLCVA at both Day 8 with 41% vs. 22% placebo and at Day 15 with 44% vs. 23%; Nyxol showed a favorable safety and tolerability profile: There were no serious adverse events; Adverse events occurring in Nyxol-treated subjects were predominantly mild in severity and were consistent with those observed in previous trials.

ShowHide Related Items >><<
OCUP Ocuphire Pharma
$2.12 /

-0.075 (-3.42%)

OCUP Ocuphire Pharma
$2.12 /

-0.075 (-3.42%)

11/24/21 H.C. Wainwright
Ocuphire Pharma initiated with a Buy at H.C. Wainwright
10/06/21 Spartan Capital
Ocuphire Pharma initiated with a Buy at Spartan Capital
06/01/21 JonesTrading
Jones Trading bullish on Ocuphire, sees 'under the radar' revenue opportunity
OCUP Ocuphire Pharma
$2.12 /

-0.075 (-3.42%)

OCUP Ocuphire Pharma
$2.12 /

-0.075 (-3.42%)

Earnings
Ocuphire Pharma reports Q1 EPS (35c), consensus (35c) » 08:08
05/13/22
05/13
08:08
05/13/22
08:08
OCUP

Ocuphire Pharma

$1.98 /

+0.11 (+5.88%)

Key anticipated future…

Key anticipated future milestones include: Planned New Drug Application with the FDA for Nyxol in RM indication in late 2022, with potential launch as first dilation reversal drop in 2H 2023; Initiate VEGA Phase 3 program in mid-2022 investigating Nyxol alone and Nyxol with 0.4% low-dose pilocarpine as adjunctive therapy and, if successful, expect to file an NDA in 2023; Report top-line results from the Nyxol Phase 3 LYNX-1 trial in 2Q 2022; Report top-line results from the APX3330 Phase 2b ZETA-1 trial in 2H 2022.

ShowHide Related Items >><<
OCUP Ocuphire Pharma
$1.98 /

+0.11 (+5.88%)

OCUP Ocuphire Pharma
$1.98 /

+0.11 (+5.88%)

11/24/21 H.C. Wainwright
Ocuphire Pharma initiated with a Buy at H.C. Wainwright
10/06/21 Spartan Capital
Ocuphire Pharma initiated with a Buy at Spartan Capital
06/01/21 JonesTrading
Jones Trading bullish on Ocuphire, sees 'under the radar' revenue opportunity
OCUP Ocuphire Pharma
$1.98 /

+0.11 (+5.88%)

OCUP Ocuphire Pharma
$1.98 /

+0.11 (+5.88%)

Hot Stocks
Ocuphire Pharma announces results from MIRA-4 pediatric safety trial » 07:13
04/28/22
04/28
07:13
04/28/22
07:13
OCUP

Ocuphire Pharma

$2.33 /

-0.05 (-2.10%)

Ocuphire Pharm announced…

Ocuphire Pharm announced positive results in the MIRA-4 pediatric safety trial investigating its product candidate Nyxol for the reversal of pharmacologically-induced mydriasis. The results demonstrated that Nyxol's efficacy and safety in pediatric subjects 3-11 years of age was consistent with that shown in previous studies conducted by Ocuphire which enrolled both adolescents and adults, showing a rapid reversal of pharmacologically-induced mydriasis, RM, and a favorable safety profile. Ocuphire plans to submit an NDA that includes the results of MIRA-1, MIRA-2, MIRA-3, and MIRA-4 with the U.S. FDA in late 2022. The company is currently evaluating partnering and distribution options for an effective and cost-efficient commercial launch of Nyxol targeted for the second half of 2023, if approved. "We are very pleased with the compelling safety results in young children from the MIRA-4 trial, marking the fourth positive data milestone in our Nyxol program in RM," said Mina Sooch, MBA, Founder and CEO of Ocuphire Pharma. "These results add to our large body of clinical data demonstrating the safety and efficacy of Nyxol for RM and may potentially support a broader label to include children as young as age 3 to older adults. The rapid and large magnitude of Nyxol response of 64% in the MIRA-4 trial is consistent with that seen in the MIRA-2 and MIRA-3 trials. We remain on track for our planned NDA submission to the FDA later this year, and if approved, Ocuphire will be well positioned for a launch in the second half of 2023 for Nyxol as the only commercially-available treatment option indicated for reversing pharmacological eye dilation. We thank the study participants, physicians, study site personnel, and everyone involved in the MIRA trials for their contributions in advancing this program."

ShowHide Related Items >><<
OCUP Ocuphire Pharma
$2.33 /

-0.05 (-2.10%)

OCUP Ocuphire Pharma
$2.33 /

-0.05 (-2.10%)

11/24/21 H.C. Wainwright
Ocuphire Pharma initiated with a Buy at H.C. Wainwright
10/06/21 Spartan Capital
Ocuphire Pharma initiated with a Buy at Spartan Capital
06/01/21 JonesTrading
Jones Trading bullish on Ocuphire, sees 'under the radar' revenue opportunity
OCUP Ocuphire Pharma
$2.33 /

-0.05 (-2.10%)

OCUP Ocuphire Pharma
$2.33 /

-0.05 (-2.10%)

Hot Stocks
Ocuphire Pharma to present at ARVO 2022 meeting, MODLive! 2022 » 09:05
04/26/22
04/26
09:05
04/26/22
09:05
OCUP

Ocuphire Pharma

$2.54 /

+0.015 (+0.60%)

Ocuphire Pharma announced…

Ocuphire Pharma announced four poster presentations by key thought leaders Drs Boyer, Devries, Katz, and Pepose on APX3330 and Nyxol at the Association for Research in Vision and Ophthalmology Annual Meeting, which will take place in Denver, CO from May 1-4, 2022. In addition, Ocuphire represented by Bindu Manne, Head of Market Development and Commercialization, will be featured in a podium discussion at the MODLive! Optometry Meeting in Nashville, TN on May 5, 2022. ARVO Annual Meeting - May 1-4, 2022: Session: New drugs, mechanisms of action and ocular toxicology: Title: The safety of APX3330, an oral drug candidate for the treatment of diabetic eye disease, in the ongoing masked 24-week ZETA-1 Phase 2 clinical trial. Dr. Boyer will present masked safety data from the ongoing ZETA-1 Phase 2b trial of oral APX3330 for the treatment of diabetic retinopathy. The results show a favorable ophthalmic and systemic safety and tolerability profile, consistent with 11 prior safety trials of APX3330 in non-ophthalmic indications. The company expects to report top-line results from the ZETA-1 trial in second half of 2022. Session:Aqueous humor dynamics, IOP, corneal disease, cytokines and growth factors. Title: Phentolamine Ophthalmic Solution Reverses Pharmacologically Induced Mydriasis in Healthy Subjects: Subgroup Analyses in the Pivotal Phase 3 MIRA-2 Randomized Controlled Trial: Ocuphire will present pre-specified subgroup analyses from the MIRA-2 Phase 3 trial of Nyxol to reverse pharmacologically-induced mydriasis. Analyses were stratified by drops, iris color, and mydriatic agent. Results showed that Nyxol rapidly reversed mydriasis by significantly returning pupil diameter to normal in 60 to 90 minutes using both one and two drops across mydriatic agents and iris colors. MIRA-2 and the recently completed MIRA-3 represent two well-controlled, confirmatory Phase 3 clinical trials evaluating Nyxol in RM to support an NDA submission with the FDA planned in late 2022. Session: IOLs and Presbyopia. Title:VEGA-1: Phentolamine Ophthalmic Solution as a Single Agent Improves Distance-Corrected Near Visual Acuity in Patients with Presbyopia" Ocuphire will present efficacy data from pre-specified endpoints in the VEGA-1 Phase 2 trial of Nyxol in presbyopia. Results demonstrated that Nyxol as a single agent provided 12 to 18 hour durability and statistically significant improvement in distance-corrected near visual acuity. In addition, results also showed a favorable safety and tolerability profile, particularly notable being the absence of headaches. VEGA-1 supports the advancement to pivotal Phase 3 trials planned for mid-2022 evaluating the efficacy of Nyxol alone and in combination with low dose pilocarpine for presbyopia. Session: IOLs and Presbyopia; Title: The Efficacy of Phentolamine Ophthalmic Solution and Low-Dose Pilocarpine to Improve Distance-Corrected Intermediate Visual Acuity in Patients with Presbyopia: Dr. Pepose will present for the first time to the scientific community efficacy data from the VEGA-1 Phase 2 trial evaluating Nyxol in combination with low-dose pilocarpine to improve distance-corrected intermediate visual acuity (DCIVA) in patients with presbyopia. The results demonstrated that Nyxol and LDP combination had statistically significant improvement in DCIVA at 1 hour with durable results through 6 hours.

ShowHide Related Items >><<
OCUP Ocuphire Pharma
$2.54 /

+0.015 (+0.60%)

OCUP Ocuphire Pharma
$2.54 /

+0.015 (+0.60%)

11/24/21 H.C. Wainwright
Ocuphire Pharma initiated with a Buy at H.C. Wainwright
10/06/21 Spartan Capital
Ocuphire Pharma initiated with a Buy at Spartan Capital
06/01/21 JonesTrading
Jones Trading bullish on Ocuphire, sees 'under the radar' revenue opportunity
OCUP Ocuphire Pharma
$2.54 /

+0.015 (+0.60%)

OCUP Ocuphire Pharma
$2.54 /

+0.015 (+0.60%)

Hot Stocks
Ocuphire Pharma appoints Pepose as CMA, announces upcoming presentations » 08:19
04/19/22
04/19
08:19
04/19/22
08:19
OCUP

Ocuphire Pharma

$2.63 /

-0.185 (-6.57%)

Ocuphire Pharma announced…

Ocuphire Pharma announced the appointment of Jay Pepose, M.D., Ph.D., as its Chief Medical Advisor, CMA. In addition, Dr. Jay Pepose, Dr. Ralph Chu, and Dr. Marguerite McDonald will deliver three presentations on Nyxol at the American Society of Cataract and Refractive Surgery, ASCRS, which will be held in Washington, D.C. from April 22-26, 2022. Dr. Pepose has served on Ocuphire's Medical Advisory Board since 2018 and Board of Directors since 2021. A specialist in refractive surgery and corneal and external diseases, he is the founder and Medical Director of the Pepose Vision Institute. He also founded the Midwest Corneal Research Foundation, now the Lifelong Vision Foundation. Mina Sooch, MBA, Founder and CEO of Ocuphire Pharma, said, "We are excited to share three podium presentations on positive efficacy data with Nyxol from our second Phase 3 trial, integrated safety data from the MIRA-2 and MIRA-3 registration trials, and positive single-agent Nyxol Phase 2 data at ASCRS. We are pleased to sponsor the ASCRS Beyond 20/20 educational series, which represents a great opportunity to connect with leading physicians and thought leaders."

ShowHide Related Items >><<
OCUP Ocuphire Pharma
$2.63 /

-0.185 (-6.57%)

OCUP Ocuphire Pharma
$2.63 /

-0.185 (-6.57%)

11/24/21 H.C. Wainwright
Ocuphire Pharma initiated with a Buy at H.C. Wainwright
10/06/21 Spartan Capital
Ocuphire Pharma initiated with a Buy at Spartan Capital
06/01/21 JonesTrading
Jones Trading bullish on Ocuphire, sees 'under the radar' revenue opportunity
OCUP Ocuphire Pharma
$2.63 /

-0.185 (-6.57%)

OCUP Ocuphire Pharma
$2.63 /

-0.185 (-6.57%)

Over a quarter ago
Hot Stocks
Ocuphire Pharma says MIRA-3 Phase 3 trial of NYXOL meets primary endpoint » 07:21
03/29/22
03/29
07:21
03/29/22
07:21
OCUP

Ocuphire Pharma

$4.23 /

-0.13 (-2.98%)

Ocuphire Pharma announced…

Ocuphire Pharma announced topline results in the MIRA-3 trial, the company's second Phase 3 registration trial investigating its product candidate Nyxol for the reversal of pharmacologically-induced mydriasis. Ocuphire announced positive results from its first Phase 3 trial, MIRA-2, in March 2021. Nyxol is a proprietary, preservative-free, stable, investigational eye drop formulation of phentolamine mesylate designed to reduce pupil size by inhibiting contraction of the iris dilator muscle. MIRA-3 was designed as a multi-center, randomized, parallel arm, double-masked, placebo-controlled Phase 3 trial evaluating the safety and efficacy of Nyxol in subjects with pharmacologically-induced mydriasis. MIRA-3 enrolled 368 subjects from November 2021 to February 2022 at 16 sites in the U.S. These topline results demonstrated that the MIRA-3 trial met its primary endpoint with 58% of subjects treated with Nyxol returning to less than or equal to 0.2 mm of their baseline pupil diameter at 90 minutes compared to only 6% of subjects treated with placebo. The effect was also significant at 60 minutes. In comparison, only 36% of placebo treated subjects returned back to baseline PD at 6 hours. These results showed clinically meaningful differences between Nyxol and placebo for accelerating reversal of pharmacologically-induced mydriasis. Highlights of MIRA-3 Efficacy and Safety Results: MIRA-3 s a Phase 3 registration trial evaluating the product candidate Nyxol to expedite the reversal of pharmacologically induced mydriasis. In the trial 368 study participants were randomized 2:1 to receive Nyxol or vehicle control 1 hour after receiving one of 3 mydriatic agents. The three mydriatic agents used in this trial were phenylephrine 2.5%, tropicamide 1%, and Paremyd, which are all commonly used in optometry and ophthalmology offices to dilate patients' pupils for annual or special exams as well as surgical procedures. The study population was comprised of subjects in the modified Intent to Treat population. Summary of MIRA-3 Topline Data: The primary endpoint was met with 58% of subjects treated with Nyxol returning to less than or equal to 0.2 mm of their baseline pupil diameter at 90 minutes compared to only 6% of placebo treated subjects across the three mydriatic agents. Key secondary efficacy endpoints also met statistical significance: Early onset of action with 42% of subjects at baseline PD by 60 minutes post-dose. Significantly more Nyxol-treated subjects returned to normal PD or smaller than placebo-treated subjects at all time points from 1 hour to 24 hours. Similar efficacy was seen with one or two drops of Nyxol. Nyxol was effective regardless of iris color or mydriatic agent used.Approximately 4 hours were gained in time to return to normal pupil diameter overall and across mydriatic agents and iris colors. Nyxol restored normal distance corrected near vision significantly faster than placebo. Nyxol demonstrated a favorable safety and tolerability profile. Nyxol was well tolerated with no serious adverse events or withdrawals due to adverse events. The only AE occurring in greater than 5% subjects was mild, transient conjunctival hyperemia. Ocuphire recently completed enrollment of 23 pediatric subjects in the MIRA-4 trial evaluating the safety and efficacy of Nyxol eye drops to reverse pharmacologically-induced mydriasis. Top line results are expected in the second quarter of 2022. If MIRA-4 meets its endpoints, the results would potentially support a broader label for Nyxol in RM to include children as young as age 3. Ocuphire is also on track to complete the Chemistry, Manufacturing and Controls section of the NDA as three registration batches of Nyxol have been completed and on stability. The company plans to file an NDA that includes the results of MIRA-1, MIRA-2, MIRA-3, and MIRA-4 with the U.S. FDA in late 2022.

ShowHide Related Items >><<
OCUP Ocuphire Pharma
$4.23 /

-0.13 (-2.98%)

OCUP Ocuphire Pharma
$4.23 /

-0.13 (-2.98%)

11/24/21 H.C. Wainwright
Ocuphire Pharma initiated with a Buy at H.C. Wainwright
10/06/21 Spartan Capital
Ocuphire Pharma initiated with a Buy at Spartan Capital
06/01/21 JonesTrading
Jones Trading bullish on Ocuphire, sees 'under the radar' revenue opportunity
04/05/21 Alliance Global Partners
Ocuphire Pharma initiated with a Buy at Alliance Global Partners
OCUP Ocuphire Pharma
$4.23 /

-0.13 (-2.98%)

OCUP Ocuphire Pharma
$4.23 /

-0.13 (-2.98%)

Earnings
Ocuphire Pharma reports Q4 EPS (35c), consensus (29c) » 08:09
03/24/22
03/24
08:09
03/24/22
08:09
OCUP

Ocuphire Pharma

$3.94 /

+0.12 (+3.14%)

"2021 proved to be a…

"2021 proved to be a highly productive year for Ocuphire with 2022 setting up to be a more transformative year given our series of late-stage data read-outs in MIRA, LYNX and ZETA trials throughout the year, ending with our first planned NDA filing. We have an ambitious vision in ophthalmology targeting highly prevalent refractive and diabetic retinal diseases with our 2 lead small molecule drug candidates," said Mina Sooch, MBA, Founder and CEO of Ocuphire Pharma. "We are pleased to rapidly exceed enrollment in and complete 4 clinical trials across Nyxol and APX3330 in the first months of 2022. At our R&D Day in January, we reported for the first time positive Phase 2 results in presbyopia for Nyxol as a single-agent. With this new chronic opportunity for Nyxol alone as a pupil modulation agent, we can potentially realize synergies in presbyopia and NVD patients. We recently held a FDA Type-C meeting and gained clear guidance for the VEGA Phase 3 presbyopia program, for which we plan to initiate in mid-2022. With the successful enrollment of the 24-week study for our retinal candidate APX3330 and the continued favorable systemic and ocular safety profile that we shared at our recent R&D Day, we are also excited to lead the retinal landscape with an oral option for diabetic retinopathy patients and report our topline data from our placebo-controlled, double-masked, Phase 2b ZETA-1 trial in the second half of 2022."

ShowHide Related Items >><<
OCUP Ocuphire Pharma
$3.94 /

+0.12 (+3.14%)

OCUP Ocuphire Pharma
$3.94 /

+0.12 (+3.14%)

11/24/21 H.C. Wainwright
Ocuphire Pharma initiated with a Buy at H.C. Wainwright
10/06/21 Spartan Capital
Ocuphire Pharma initiated with a Buy at Spartan Capital
06/01/21 JonesTrading
Jones Trading bullish on Ocuphire, sees 'under the radar' revenue opportunity
04/05/21 Alliance Global Partners
Ocuphire Pharma initiated with a Buy at Alliance Global Partners
OCUP Ocuphire Pharma
$3.94 /

+0.12 (+3.14%)

OCUP Ocuphire Pharma
$3.94 /

+0.12 (+3.14%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.